热门资讯> 正文

Koherus BioSciences 2025年第四季度盈利预览

2026-03-09 05:35

Coherus生物科技(CHRS) 0

Coherus BioSciences (CHRS) is scheduled to announce Q4 earnings results on Monday, March 9th, after market close.
The consensus EPS Estimate is -$0.31 (-10.7% Y/Y) and the consensus Revenue Estimate is $14.09M (-74.0% Y/Y).
Over the last 2 years, CHRS has beaten EPS estimates 13% of the time and has beaten revenue estimates 63% of the time.

More on Coherus BioSciences

Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
Coherus Oncology prices stock offering to raise $50.1M
Coherus Oncology announces proposed public offering of common stock

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。